Jonathan Finn is Director at ATOSSA THERAPEUTICS, INC. (ATOS). They have made 1 open-market trade across 1 company since 2024, most recently 2026-05-12.
CIK 0001981595
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $44K since 2024, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATOS | BUY | 2024-04-10 | 2024-04-11 | $1.77 | $44K | -18.6% | -20.2% | -34.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.